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PURPOSE. Dense deposit disease (DDD) is caused by dysregulation of the alternative pathway
of the complement cascade and characterized by electron-dense deposits in the kidney
glomerular basement membrane (GBM) and drusen in Bruch’s membrane (BrM). Complement
factor H (fH) and factor properdin (fP) regulate complement activation; fH inhibits alternative
pathway (AP) activation, whereas fP promotes it. We report pathologic changes in eyes of an
fH and fP double-mutant mouse, which we previously showed have dense deposits in the
GBM and early mortality from nephropathy.
METHODS. fHm/m, fP/, and fHm/m/fP/ mice were generated on a C57BL/6–129J
background. Fundus imaging at 8 weeks of age was followed by analysis via light and
electron microscopy. Retinal function was assessed by electroretinography (ERG). Comple-
ment levels and localization were tested by immunohistochemistry and ELISA. Retinas of
fHm/m/fP/ mice treated with intraperitoneal injections of an anti-C5 antibody were
compared to those of age- and genotype-matched mice injected with an isotype control
antibody.
RESULTS. fHm/m/fP/ mice suffered early-onset retinal hypopigmented spots detected using in
vivo retinal photography, and histologic examination showed basal laminar deposits (BLamD),
degeneration of the photoreceptors, and RPE vacuolization. ERG showed diminished retinal
function. The anti-C5 antibody was retina-protective.
CONCLUSIONS. This unique mouse represents a new model of complement-mediated rapid-
onset DDD, and could be useful in exploring the pathologic changes associated with BLamD
in age-related macular degeneration.
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Dense deposit disease (DDD) and C3 glomerulonephritis(C3GN) are rare forms of glomerulonephritis that affect
children and young adults.1,2 Both diseases result from
abnormal regulation of the alternative pathway of the
complement system and are now classified under the heading
of ‘‘C3 glomerulopathies.’’ DDD (also known as membrano-
proliferative glomerulonephritis type II) is characterized by
electron-dense deposits in the glomerular basement membrane
(GBM) as well as drusen in Bruch’s membrane (BrM).1 There
currently are no mechanism-directed therapies to treat affected
patients, approximately 50% of whom progress to having end-
stage renal disease within 10 years of diagnosis.1 The
composition of drusen in patients with DDD is similar to that
in patients with age-related macular degeneration (AMD): both
types contain lipids, cholesterol, amyloid P component,
vitronectin, and complement components C5 and C5b-9.3,4
This is consistent with the current understanding that DDD and
AMD share a complement-mediated pathogenesis.5 Unlike in
AMD, however, drusen in individuals with DDD form at an early
age and often are detected in the second decade of life with a
variable distribution within the retina.6–8 Over time, atrophic
changes can occur in the neurosensory retina (NSR) and RPE,
thereby causing deterioration of vision. Late-stage complica-
tions include choroidal neovascularization and central serous
retinopathy.6
As a component of the innate immune system, complement
has a key role in recognizing and fighting infections.9
Complement is activated via three pathways: the classical,
lectin, and alternative pathways (AP). AP dysregulation has
been found in many complement-mediated human diseases,
including AMD.10–12 Among several proteins that regulate AP,
complement factor H (fH) is an abundant plasma regulator
inhibiting the activity of C3 convertase C3bBb on the cell
surface and in the fluid phase.13–15 fH has 20 short consensus
repeat (SCR) domains, and the N-terminal SCRs 1 to 4 are
responsible for complement regulation. Polymorphisms in fH
are associated with AMD, especially the common Y402H
variant in SCR 7,16 which contains the overlapping binding
sites for heparin, C-reactive protein (CRP), and streptococcal M
protein.17 C3GN, DDD, and atypical hemolytic uremic syn-
drome (aHUS) also are associated with fH mutations.1,2,15,18
In opposition to fH, properdin, or complement factor P (fP),
positively regulates AP activation by stabilizing C3bBb, signif-
icantly increasing its half-life.19 It has 6 thrombospondin type 1
repeat (TSR) domains, and TSRs 5 and 6 mediate its
oligomerization and function. fP circulates in plasma and,
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unlike any other complement protein, is produced primarily by
leukocytes instead of hepatocytes. Accordingly, fP levels are
elevated in inflammatory microenvironments.20 Properdin-
deficient mice have been used as models to study arthritis,21,22
ischemic-reperfusion injury,23 abdominal aortic aneu-
rysms,24,25 asthma,24,26 septic27 and nonseptic shock,28 and
C3 glomerulopathy.29,30
Previously, we created an fH mutant mouse by inserting two
stop codons at the beginning of SCR 19 of the fH gene to
selectively disrupt function of the C-terminal domain of fH to
model aHUS-related mutations in this region.30 Unexpectedly,
our fH mutant mouse had impaired fH activity in the fluid
phase and on the cell surface due to expression of only a small
amount of the truncated fH protein in the plasma, and a
nonlethal form of C3 glomerulopathy developed instead of
aHUS.30 When this fH mutant mouse was rendered deficient in
fP either by genetic deletion or by antibody neutralization,
paradoxically a more severe and lethal form of C3 glomeru-
lopathy developed showing kidney injury on electron micros-
copy similar to human DDD.30 We characterized pathologic
changes in the retina of this mouse model, finding rapid-onset
hypopigmented spots representing RPE degeneration detected
by fundus photography, and histologic evidence of sub-RPE
basal laminar deposits (BLamD), as well as RPE and photore-
ceptor (PR) degeneration. Because this unique mouse model
exhibits retinal manifestations similar to those in DDD, it could




Generation of fHm/m, fP/ and fHm/m/fP/ on a C57BL/6–129J
mixed background were described previously.21,30 All mice
were housed in a UPenn nonbarrier facility maintained at 21-
238C, a 12-hour/12-hour light-dark cycle, and free access to
food and water. All experiments used age-matched littermates
as controls. Mice were negative for the rd1 and rd8 mutations.
Experimental procedures were performed in accordance with
the Association for Research in Vision and Ophthalmology
(ARVO) Statement for the Use of Animals in Ophthalmology
and Vision Research. All protocols were approved by the
animal care review board of the University of Pennsylvania.
Most fHm/m/fP/ mice had to be euthanized between 8 and 12
weeks due to renal failure.30 However, all mice used in this
study were not critically moribund.
Fundus Imaging
Mice were anesthetized with a single intraperitoneal injection
of ketamine (80 mg/kg) xylazine (40 mg/kg), and aceproma-
zine (2 mg/kg). Pupils then were dilated with 1% tropicamide
(Mydriacyl; Alcon, Fort Worth, TX, US). Once sufficiently
anesthetized, mice were placed on a padded metal stage. Color
and autofluorescence images then were acquired using a
fundus camera (Micron III; Phoenix Research Laboratories,
Inc., Pleasanton, CA, USA).
Morphologic Analysis
Electron microscopy on retinal samples was performed as
described previously.31 After enucleation, eyes were fixed in
2% paraformaldehyde/2% glutaraldehyde overnight at 48C. The
anterior segment was removed, and the posterior portion of
each eye was cut into small wedge-shaped pieces and post-
fixed in 1% osmium tetroxide/0.1 mol/L sodium cacodylate
buffer, dehydrated, and embedded in EMbed-812 (Electron
Microscopy Sciences, Hatfield, PA, USA). Ultrathin sections
(60–80 nm thick) were stained and examined with a JEOL1010
transmission electron microscope (JEOL Ltd., Tokyo, Japan).
Images were acquired with Advanced Microscopy Techniques
Image Capture software version 602 (Advanced Microscopy
Techniques Corp., Woburn, MA, USA) and were rotated and
cropped with Adobe Photoshop CS5 (Adobe Systems Incorpo-
rated, San Jose, CA, USA).
The following strategy was used to quantify RPE and BrM
degeneration.32 (1) Continuity of sub-RPE deposits: 0, no
deposits; 1, occasional deposits; 2, deposits extending <2 RPE
cells; 3, deposit extending ‡2 RPE cells. (2) Thickness of
deposits: 0, no deposits; 1, flat deposits; 2, thickness of
deposits <25% of RPE thickness; 3, thickness of deposits >25%
of RPE thickness. (3) Nature of deposit content: 0, no deposits;
1, homogenous deposit; 2, banded structure in deposits; 3, ‡3
banded structures in deposits. (4) BrM abnormality: 0, normal;
1, collagenous thickening without deposits; 2, thickening with
circular profiles or nonspecific debris; 3, banded structures,
granular material or membranous debris. Severity score of 0 to
12 was determined on each specimen by adding the scores of
the aforementioned categories. Scoring was performed for 10
micrographs per eye at 320,000 magnification at equal
intervals, and a mean score for each eye was calculated. One
eye was analyzed from each mouse.
Light Microscopy on Retinal Plastic Sections
Enucleated eyes were immersion-fixed in 2% paraformalde-
hyde/2% glutaraldehyde overnight at 48C. The tissues then
were dehydrated in increasing concentrations of ethanol,
infiltrated overnight, and embedded the next day in a water-
soluble, 2-hydroxyethyl methacrylate (HEMA) plastic resin (JB4
Solution A, Polysciences, Inc., Warrington, PA, USA). For
standard histology, 3-lm thick plastic sections were cut in the
sagittal plane and toluidine blue–stained as described previ-
ously.31 The number of nuclei per column of outer nuclear
layer (ONL) PRs was counted in triplicate at 200 lm intervals
from the optic nerve head (ONH) to 1800 lm from the ONH,
using image analysis software (ImagePro Plus 4.1; Media
Cybernetics, Silver Spring, MD, USA) to calculate distances
from manually set lengths.
Immunofluorescence
After the globes were fixed in 4% paraformaldehyde, eyecups
were generated by removing the anterior segment. The
eyecups were infiltrated in 30% sucrose overnight and
embedded in Tissue-Tek O.C.T. compound (Sakura Finetek,
Torrance, CA, USA). Immunofluorescence was performed on
sections 10 lm thick as described previously.31 After incuba-
tion with FITC-conjugated goat anti-mouse C3 antibody
(#0855500 MP Biomedicals, Solon, OH, USA) and anti-
rhodopsin antibody (ab5417, Abcam, Cambridge, MA, USA),
the sections were analyzed by fluorescence microscopy with
identical exposure parameters (model TE300 microscope;
Nikon, Tokyo, Japan) with ImagePro software (Media Cyber-
netics). Control sections were treated with a goat IgG FITC-
isotype antibody (ab37374; Abcam).
Electroretinography (ERG)
ERG recordings were performed as described previously.33 In
brief, mice were dark-adapted overnight and then anesthetized
with a mixture delivering (in mg/kg body weight) 100 ketamine, 2
xylazine, and 2 acepromazine. After pupils were dilated, and mice
were placed on a stage maintained at 378C. The ERG apparatus
was modified by the manufacturer for experiments with mice by
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substituting light-emitting diodes with emission maximum at 365
nm for standard blue ones. The stage was positioned in such a way
that the mouse’s head was located inside the stimulator (Color-
Dome; Diagnosys LLC, Lowell, MA, USA); thus, ensuring uniform
full-field illumination.
C5 ELISA
To measure levels of intact C5, 96-well ELISA plates were
coated with 5 lg/mL anti-mouse C5 monoclonal antibody
(mAb) BB5.1 in 0.1 M carbonate buffer overnight at 48C. Plates
were washed after each step with PBS/0.5% Tween-20 (PBS-T).
Plates then were blocked with 1% BSA-PBS for 1 hour at room
temperature (RT) followed by addition of serially diluted
mouse plasma samples in 1% BSA-PBS starting at 1:10. After
incubation with plasma for 1 hour at RT, the plate was washed
three times with PBS-T and then incubated with horseradish
peroxidase goat polyclonal anti-human C5 Ab (cross-reacts
with mouse C5, 1:1000; Quidel, CA, USA) for 1 hour at RT.
After washing, the plate was developed using OptEIA substrate
(BD Biosciences, San Jose, CA, USA).
Anti-C5 Antibody Treatment
fHm/m/fP/ mice were treated systemically by intraperitoneal
administration of an anti-C5 mAb (BB5.1), 1 mg twice weekly
for 12 weeks starting at 4 weeks of age. All mice weighed 20-25
g during injections. Mice in the control group were treated
with an isotype control mAb (purified from MoPC-31C
hybridoma; American Type Culture Collection [ATCC], Mana-
ssas, VA, USA) at the same dosage and frequency but only for 4
weeks due to early mortality from kidney disease.
Statistical Analysis
The means 6 SEM were calculated for each comparison pair.
Statistical analyses for hypopigmented spot counting, ERG and
C5 ELISA were performed in GraphPad Prism 6.0 (San Diego,
CA, USA) using the 1-way ANOVA with a Tukey post hoc test
comparing the mean of each group with the mean of every
other group. ONL thickness (nuclei) in plastic sections were
compared using 1-way ANOVA with post hoc pairwise
comparisons using Bonferroni adjustment. P < 0.05 was
considered statistically significant.
RESULTS
fHm/m/fP/ Mice had Hypopigmented Lesions
Detected by Fundus Photography at 8 Weeks of Age
To profile ophthalmic changes, we performed fundus photog-
raphy of mice at 8 weeks of age. No apparent pathology was
noted on fundus photographs of wild type (WT; n¼8, Fig. 1A),
fHm/m (n¼8, Fig. 1B), and fP/ (n¼8, Fig. 1C) mice. However,
hypopigmented spots were observed in fHm/m/fP/ mice (n¼
16; Fig. 1D, white arrowheads). Hypopigmented spots were
visible as early as age 4 weeks. The numbers of hypopigmented
lesions then were quantified and analyzed. Interestingly, male
fHm/m/fP/ mice (n ¼ 8) had significantly higher numbers of
lesions than female fHm/m/fP/ (n¼ 8) or other genotype (n¼
8 for each, Fig. 1E) mice. If the observed hypopigmentation
involved activation of complement factor C5, the sex
difference in fHm/m/fP/ mice would agree with previous
studies showing male mice to have higher basal serum C5
levels than females.34,35 No significant differences were
observed between sexes in WT, fHm/m, and fP/mice (data
not shown). Histologic studies demonstrated that those
hypopigmented spots are vacuolar degeneration of the RPE
(Figs. 1F, 1G, red frames).
Electron Microscopy (EM) Revealed RPE and BrM
Abnormalities in fHm/m/fP/Mice at 8 Weeks of
Age
EM was performed to compare WT (Figs. 2A, 2B) and fHm/m/
fP/ (Figs. 2C–J) mice. fHm/m/fP/ mice exhibited hypertro-
phic RPE cells (Fig. 2C, arrowhead) with subretinal debris (Fig.
2C, arrows). Some RPE cells in fHm/m/fP/ mice contained
vacuoles (Figs. 2D, 2I, 2J, asterisks) and also more melano-
somes (Fig. 2D) than RPE cells in WT (Fig. 2B). Other fHm/m/
fP/ RPE cells contained fewer melanosomes (Fig. 2E) as well
as melanosome aggregates (Figs. 2E, 2F, arrows). Additional
observations included extruded PR nuclei in the outer segment
layer (Fig. 2G, arrow) and deposits (Figs. 2D, 2F, 2H, circles)
located between the RPE plasma membrane (Figs. 2B, 2D, 2F,
2H, green arrowheads) and elastic layer of BrM (Figs. 2B, 2D,
2F, 2H, black arrowheads). Given the location of the deposits,
these appear to be BLamD, which were patchy and present in
approximately one-third of imaged sections. They were more
prevalent near the optic nerve and in the mid-periphery, and
rare in the periphery. They were not correlated with
hypopigmented spots on fundus photography nor with RPE
and PR abnormalities.
High magnification images of RPE and BrM revealed normal
morphology in WT (Fig. 3A), fHm/m (Fig. 3B), and fP/ (Fig.
3C) mice. In comparison, fHm/m/fP/ mice exhibited BLamD
(Figs. 3D, 3F, arrows) and BrM thickening (Fig. 3E). To quantify
this RPE and BrM degeneration, we categorized and scored
each EM image, revealing that fHm/m mice (n ¼ 3) and fP/
mice (n¼ 3) had severity scores that were significantly higher
than those of WT (n¼ 4, Fig. 3G; *P < 0.05) mice. Female (n¼
4) fHm/m/fP/ mice had significantly higher severity scores
than WT and a higher mean score than those of fHm/m and fP/
mice (*P < 0.05, ***P < 0.001). Notably, the severity score of
FIGURE 1. Fundus photographs and plastic sections at 8 weeks of age.
Images for (A) WT, (B) fHm/m, (C) fP/, and (D) fHm/m/fP/ mice.
Arrowheads denote hypopigmented lesions. (E) Numbers of hypopig-
mented lesions per fundus field. Male fHm/m/fP/ mice (n ¼ 8) had
significantly more lesions than female fHm/m/fP/ mice (n ¼ 8) and
other genotypes (n ¼ 8 in WT, fHm/m, and fP/). Plastic sections
revealed RPE vacuolization at the locations corresponding to hypopig-
mented lesions displayed on fundus images (F, G; red frames) **P <
0.01; ***P < 0.001. Scale Bars: mean 6 SEM. IPL, inner plexiform layer;
INL, inner nuclear layer.
BLamD in fH/fP Mouse IOVS j July 2018 j Vol. 59 j No. 8 j 3407
Downloaded From: https://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/937362/ on 08/23/2018
male fHm/m/fP/ mice (5.70 6 1.70) was much higher than
that of females (2.35 6 0.29), although there was larger
variation in severity scores within the male group.
Histology Showed PR Death and RPE Degeneration
in fHm/m/fP/Mice at 8 Weeks of Age
Morphologic analysis was performed at 8 weeks of age. Plastic
sections of WT (Fig. 4A), fHm/m (Fig. 4B), and fP/ (Fig. 4C)
mice revealed normal retinal morphology. In contrast, sections
from fHm/m/fP/ mice revealed ONL thinning (Fig. 4D), and
disrupted inner and outer segments (Fig. 4E) in fHm/m/fP/
mice. Finally, ONL thickness measurement via counting of PR
FIGURE 2. EM analysis on WT and fHm/m/fP/ retinas. Low (left
column) and high (right column) magnification EMs compare (A, B) WT
to (C–J) fHm/m/fP/ mice. (C) fHm/m/fP/ mice exhibited hypertrophic
RPE cells (arrowhead) with subretinal debris (arrows). (D) Some RPE
cells in fHm/m/fP/ mice contained more melanosomes compared to
WT, and also contained vacuoles (asterisk). (E) Other RPE cells had
fewer melanosomes compared to WT. (F) Some RPE cells contained
melanosome aggregates (arrow). (G) Extruded PR nuclei migrating
toward the RPE were noted (arrow). (I, J) Multiple vacuoles (asterisks)
were found in the RPE cells. (D, F, H) Basal laminar deposits (circles)
were observed. (B, D, F, H) Green arrowheads indicate the basolateral
RPE plasma membrane. Black arrowheads indicate the elastic layer of
BrM. (A, C, E, G, I) Scale bar: 10 lm. (B, D, F, H, J) Scale bar: 1.5 lm.
CC, choriocapillaris; BI, basal infolding; Nu, nucleus.
FIGURE 3. High magnification (320,000) EM images of RPE and BrM.
Normal morphology in (A) WT (B) fHm/m mice, and (C) fP/ mice. In
contrast, (D–F) fHm/m/fP/ mice exhibited basal laminar deposits
(arrows) located between the basolateral RPE plasma membrane
(green arrowheads) and elastic layer of BrM (black arrowheads), as
well as (E) BrM thickening. Scale bar: 1.5 lm. (G) Pathologic severity
score calculations (maximum score ¼ 12). WT mice (n ¼ 4) exhibited
little, if any, pathology (severity score 0.02 6 0.02). fHm/m mice (n¼ 3)
exhibited mild pathology (1.73 6 0.58), as did fP/ mice (n¼ 3; 0.97
6 0.07). fHm/m/fP/ female mice (n ¼ 4) had somewhat worse
degeneration than fHm/m and fP/ mice (2.35 6 0.29). However,
fHm/m/fP/ male mice (n ¼ 4) had considerably greater degeneration
and much wider variability in scores than all three previous groups
(5.70 6 1.70). *P < 0.05, ***P < 0.001. Severity scores are presented as
mean 6 SEM.
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FIGURE 4. Morphometric analysis of plastic sections from male mouse retinas. Photomicrographs of plastic sections from (A) WT, (B) fHm/m, and
(C) fP/ mice revealed normal retinal histology. In contrast, sections from (D–F) fHm/m/fP/ mice demonstrated (D) ONL thinning, and (E)
disrupted IS and OS. (F) ONL thickness was measured via counting of PR nuclei per column. Measurements were made in triplicate at intervals of
200 lm for a total range of 2000 lm on either side of the optic nerve (reference point 0 on the x-axis). There were no significant differences among
WT (n¼3), fHm/m (n¼3), and fP/ (n¼3) mice. In comparison, the ONL in fHm/m/fP/ mice (n¼3) was significantly thinner. Asterisks represent
significant differences between fHm/m/fP/ and WT mice. *P < 0.05. (A–D) Scale bar: 25 lm. (E) Scale bar: 50 lm. GCL, ganglion cell layer.
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nuclei revealed a significantly thinner ONL in fHm/m/fP/ mice
compared to other genotypes (Fig. 4F).
Fluorescence Photomicrographs Showed
Increased C3 Staining in fHm/m/fP/ Mice
Previously, deposition of C3 in the kidneys of fHm/m mice was
found in mesangium and along the capillary loops of glomeruli.
However, C3 staining was brighter and restricted to the
capillary loops in glomeruli of fHm/m/fP/ mice.30 To
determine whether the retina also had C3 deposits, we
performed immunolabeling for C3 in the retina (Fig. 5).
Compared to WT, fHm/m, and fP/ mice (Figs. 5A–C), we
detected prominent sub-RPE C3 deposition in fHm/m/fP/
mice (Figs. 5D, 5E, 5K, 5L). Choroidal labeling also was
observed in some fHm/m/fP/ mice (Fig. 5D), while in other
mice patches of PR outer segments also were stained (Fig. 5E).
Higher magnification images that were costained with an
antibody against RPE65 further highlighted the sub-RPE C3
deposition in fHm/m/fP/ mice (Figs. 5H–K). Pixel density
analysis revealed a significantly increased C3 signal in the sub-
RPE/BrM space of fHm/m/fP/ mice (Fig. 5G). Double-labeling
with anti-rhodopsin antibody, which labels the PR outer
segments (IS/OS; Fig. 5M), confirmed C3 deposits in the sub-
FIGURE 5. Fluorescence photomicrographs showed more C3 staining in fHm/m/fP/ mice. Relative to (A) WT, (B) fHm/m, (C) fP/, and (F) labeling
with isotype control antibody in fHm/m/fP/ retinas, the C3 signal in (D, E) fHm/m/fP/ mice was more striking and localized in (D) sub-RPE areas,
choroid, and (E) PR outer segments. (G) Mean pixel density of fluorescence showed that C3 signal in the sub-RPE/BrM region was significantly
higher in fHm/m/fP/ (n¼ 5) than in other genotype (n¼ 2 in WT, fHm/m, and fP/) mice. *P < 0.05; **P < 0.01. Scale bars: mean 6 SEM. (H–K)
Higher magnification images with RPE65 staining showed that the C3 signal is more prominent under the RPE cells in (K) fHm/m/fP/ compared to
(H) WT, (I) fHm/m, and (J) fP/mice. In contrast with rhodopsin signal in PR OS (M), C3 is localized in the OS and sub-RPE region (L, N). (A–F, L–N)
Scale bar: 100 lm. (H–K) Scale bar: 50 lm.
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RPE region and in small patches of outer segments (Figs. 5L–
N).
ERG Showed Reduced Amplitudes in fHm/m/fP/
Mice
We performed ERG to assess retinal PR function. The rod-b
(Fig. 6A), rod-a (Fig. 6B), and cone b-wave (Fig. 6C) amplitudes
were lower in male fHm/m/fP/ mice relative to females and to
the other genotypes. The reduction relative to WT was
significant in rod-b and rod-a waves (Figs. 6A, 6B; **P < 0.01).
Properdin Deficiency Increases Plasma C5 Levels
in fHm/m Mice and Anti-C5 Antibody can Rescue
the Retinal Degeneration
Previously, we found a significant increase of intact C3 and C5
in the plasma of fHm/m/fP/ mice compared to fHm/m mice,
indicating that fP deficiency partially decreased AP and
terminal complement consumption.30,36 Restoration of plasma
C5 in fHm/m/fP/ mice was confirmed in the current study
(Fig. 6D). Male (n¼9) and female (n¼7) fHm/m/fP/ mice had
significantly higher serum C5 levels than fHm/m mice (n¼4, **P
< 0.01, ***P < 0.001). There was no significant difference in C5
levels between fHm/m/fP/ males and WT mice (n ¼ 4),
whereas levels in fHm/m/fP/ females were significantly
reduced compared to WT mice (*P < 0.01). In a previous
study of lethal glomerulonephritis in fHm/m/fP/ mice, we
demonstrated that blocking C5 with a monoclonal antibody
starting at 4 weeks of age prevented renal disease and death.36
To determine if rapid onset retinopathy in fHm/m/fP/ mice
also is mediated by C5, we treated a group of fHm/m/fP/ mice
with either an anti-C5 mAb (n¼ 8) or an isotype control mAb
(n ¼ 4). Specifically, the anti-C5 mAb binds to and inhibits
cleavage of intact C5 into C5a and C5b. Each mouse (weighing
20–25 g) received 1 mg of mAb per injection, given that
previous studies with the BB5.1 clone showed that 1 mg
reduced up to 80% of serum hemolytic activity.37 Treatment
started at 4 weeks of age, continuing for 12 weeks in the anti-
C5 mAb group but only 4 weeks in the control mAb group due
to early mortality. We found that fHm/m/fP/ mice treated with
the anti-C5 mAb had fewer hypopigmented lesions on fundus
photography compared to control antibody-treated mice (Fig.
6E), This significant difference was even more impressive given
that the anti-C5 mAb group was 8 weeks older than the control
mAb group, potentially allowing for more age-dependent
retinal degeneration. Correspondingly, ERG amplitudes also
were higher in fHm/m/fP/ mice treated with anti-C5 mAb (Fig.
6F). In particular, the difference in rod-a wave amplitudes was
significant.
DISCUSSION
We reported a mouse model of retinopathy seen in human
DDD. Key changes in the eyes of our fHm/m/fP/ mice that
FIGURE 6. ERG and hypopigmented spots in different groups of mice. (A) rod-b, (B) rod-a, and (C) cone b-wave amplitudes were lower in male
fHm/m/fP/ (n¼ 8) compared to female (n¼ 8), fHm/m (n¼ 8), fP/ (n¼ 4), and WT (n¼ 8) mice. Differences in amplitude for rod-b and rod-a
waves between male fHm/m/fP/ and WT mice were statistically significant. (D) male fHm/m/fP/ (n¼ 9) and female (n¼ 7) mice had significantly
higher serum C5 levels than fHm/m mice (n¼4), and there was no significant difference in C5 levels between fHm/m/fP/male and WT mice (n¼4).
(E) In fHm/m/fP/ mice that received systemic anti-C5 antibody treatment (n¼ 5), the numbers of hypopigmented spots on fundus imaging were
significantly decreased compared to mice treated with control antibody (n¼ 4). (F) ERG amplitudes were higher in fHm/m/fP/mice treated with
anti-C5 antibody (n¼8) compared to control antibody (n¼5), and the rod-a wave amplitude was significantly protected. *P < 0.05; **P < 0.01, ***P
< 0.001. Scale bars: mean 6 SEM.
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mirror human pathology include white spots on fundus
imaging, PR death, and RPE pigmentary changes. In addition,
we detected reductions in rod-b and –a wave amplitudes on
ERG, which also is observed in patients with DDD when they
suffer nyctalopia.38,39
The choriocapillary–BrM–RPE interface and the capillary
tuft–GBM–epithelial interface are strikingly similar, which may
explain why DDD patients sometimes have concurrent dense
deposit pathology in the kidney and eye.4 Patients typically do
not experience visual symptoms until 10 to 15 years after
diagnosis, when retinal atrophy and RPE clumping cause
impairments in visual acuity and visual fields. Eventually, a large
proportion of patients with DDD have multiple sub-RPE drusen
that appear yellowish-white on funduscopy.8,40,41 The drusen
usually are found clustered in the macula, although larger soft
drusen in other regions also can be present. These drusen are
histopathologically similar to the GBM deposits.3,4,8 Further
loss of visual acuity or fields may result from additional
complications, including subretinal neovascularization, retinal
detachment, and central serous retinopathy.42,43
Ultrastructural analysis in our fHm/m/fP/ mice revealed
BLamD. These deposits form between the RPE and RPE basal
lamina as discrete pockets in aging normal eyes, but as a
continuous layer in AMD eyes.44–47 A continuous layer of
BLamD under the fovea is considered by some investigators to
be a histologic definition of AMD,48 and has been associated
with advanced AMD risk.45 The primary components of
BLamD are fibrous long-spacing collagen, as well as esterified
and unesterified cholesterols.44 It has been hypothesized that
by separating the RPE from its basal lamina, BLamD may
promote transport of membranous debris into the inner
collagenous zone of BrM. This debris then may accumulate
and facilitate formation of basal linear deposits and soft
drusen.49
In addition, BLamD can contain complement components,
including C3.46 Because we detected increased C3 immuno-
labeling in the BrM of fHm/m/fP/ mice, complement
activation and deposition is likely to contribute to BLamD
formation in our model. Moreover, since C3 circulates in serum
and is produced/secreted locally by the RPE,50–52 C3 from both
sources may contribute to the observed deposits.
However, BLamD is not limited to AMD eyes. Although the
presence of BLamD is 80% sensitive for AMD in eyes over 60
years old, it only has a specificity of 18%.53 Indeed, BLamD has
been identified in various mouse models of aging as a more
general marker of RPE stress.54 Environmental stressors also
have caused formation of BLamD, including cigarette smoke
exposure55 and laser photochemical injury56 in mice on a high-
fat diet. In humans, BLamD has been reported in other adult-
onset forms of retinal degeneration, including Sorsby fundus
dystrophy, late-onset retinal degeneration, and Malattia Lev-
entinese/Doyne’s honeycomb retinal dystrophy.57–59 BLamD
was reported previously in an fH knockout mouse model that
exhibited pathologic changes in the kidney.60,61 We added to
this observation by showing that the fH/fP double mutant
mouse model of lethal DDD had significant BLamD. Further,
while the fH knockout mice were characterized at 8 to 24
FIGURE 7. Schematic for alternative complement pathway activity in fHm/m/fP/ mice. (A) The fH truncation mutation impaired cell surface
attachment and also caused low level expression of fH, resulting in uncontrolled AP complement activation in the fluid phase with near complete
C3 and C5 depletion. The fH mutation combined with the fP- knockout reduced fluid phase C3 and C5 consumption and elevated plasma C3 and C5
levels. (B) With a low level of truncated fH and impaired fH function, excess AP complement activation occurred in an fP-independent manner,
leading to C3b accumulation in the PR IS/OS and sub-RPE/BrM region and terminal complement-mediated local tissue injury. The anti-C5 antibody
used in our experiments likely impaired MAC formation, resulting in decreased hypopigmented spots on fundus imaging and improved ERG
amplitudes. PRL, PR layer.
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months, our mice were studied at 8 weeks of age, showing
accelerated degeneration.
The aforementioned pathologic changes in fHm/m/fP/
mice resulted from modifications to the AP of complement
that led to increased autologous complement-mediated tissue
injury. The fH mutation impaired fH cell surface attachment,
and in theory would render retinas more susceptible to
complement-mediated damage. However, due to low expres-
sion of the truncated fH and consequent lack of sufficient AP
complement regulation in the fluid phase, C3 and C5 were
largely consumed, and this paradoxically protected the kidney
and eye from more severe injury in fHm/m mice (Fig. 7A).
Previously, we found that C3 and C5 consumption was reduced
in fHm/m/fP/ mice compared to fHm/m mice,30,36 suggesting
that fP-deficiency resulted in more C3 and C5 available to
damage the kidney and eye in an fP-independent manner.62
With impaired fH, excess C3b accumulated in the PR outer
segments and sub-RPE/BrM regions (Fig. 7B). Furthermore, the
efficacy of anti-C5 antibody in reducing hypopigmented spots
on fundus imaging and improving ERG amplitudes suggested
that terminal complement was excessively activated and
contributed to the eye phenotype of fHm/m/fP/ mice.
An important question concerning complement-mediated
retinopathy is the relative contributions of local versus
systemic complement. Toomey et al.60 reported that RPE
degeneration with vision loss was induced by a high fat diet
only in 2-year-old fHþ/ mice, but not in fH/ mice because of
retention of serum C3 in fHþ/ mice versus complete serum C3
consumption in fH/ animals.60 This is consistent with our
results showing that higher C3 and C5 levels in fHm/m/fP/
mice relative to fHm/m mice led to more C3 and C5 activation in
the kidney and eye, with consequent degeneration of those
tissues. Our finding that administration via intraperitoneal
injection of anti-C5 mAb ameliorated local retinopathy in
fHm/m/fP/ mice further supports the role of systemic
complement in contributing to retinal injury in the setting of
fH dysfunction.
Interestingly, male fHm/m/fP/ mice exhibited more severe
retinal pathology than females. A potential reason for this
difference is that male mice have higher baseline serum C5
levels, which has been attributed to differences in sex
hormones, such as testosterone.34,35 In support of this
hypothesis, we found that intact C5 levels were significantly
lower in female fHm/m/fP/ compared to WT mice, whereas
there was no difference between male fHm/m/fP/ and WT
mice. In addition, there was significant variability in phenotype
severity among male fHm/m/fP/ mice, including two mice
with no hypopigmented spots on fundus photographs. This
indicated incomplete penetrance of the fHm/m/fP/ mutations,
similar to the penetrance of defects induced by fH mutations in
other organs, such as the kidney.
Our finding that anti-C5 mAb therapy ameliorated retinop-
athy in fHm/m/fP/ mice suggested that C5 activation
participated in the eye pathophysiology of this DDD mouse
model. This result is consistent with our recent study showing
that blocking C5 also prevented lethal glomerulonephritis in
fHm/m/fP/mice.36 A recent study testing anti-C5a therapy in a
fHþ/ mouse model on a high fat diet showed that the
treatment was ineffective.63 Perhaps an anti-C5 therapy that
blocks C5a and membrane attack complex (MAC) formation
would be more effective, as in our study. Furthermore, our
results suggested a potential therapeutic role for anti-C5
therapy to treat retinopathy associated with DDD. Current
guidelines recommend an ophthalmic exam on presentation
and annual screenings beginning 10 years after diagnosis, with
prompt treatment for neovascular membranes.42 Investigations
of new treatment strategies for DDD-associated retinopathy are
especially useful given that increasing survival after renal
transplantation will likely increase its prevalence.6
In summary, we characterized the fHm/m/fP/ mouse as a
novel model of DDD-related retinopathy, with notable BLamD
formation. The efficacy of systemic anti-C5 antibody treatment
suggested that serum complement contributes to the observed
pathology. This unique mouse represents a new tool to study
complement-mediated rapid-onset retinal disease and RPE
stress, and is a useful model to study BLamD in the absence
of age-related confounding variables. Future directions for
research include using electroretinography to assess RPE
function in this model, dissecting how complement dysfunc-
tion may be associated with melanosome abnormalities, and
determining which complement components are necessary for
BLamD formation and for RPE/PR degeneration.
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